Author: Pang, Jiaojiao; Xu, Feng; Aondio, Gianmarco; Li, Yu; Fumagalli, Alberto; Lu, Ming; Valmadre, Giuseppe; Wei, Jie; Bian, Yuan; Canesi, Margherita; Damiani, Giovanni; Zhang, Yuan; Yu, Dexin; Chen, Jun; Ji, Xiang; Sui, Wenhai; Wang, Bailu; Wu, Shuo; Kovacs, Attila; Revera, Miriam; Wang, Hao; Jing, Xu; Zhang, Ying; Chen, Yuguo; Cao, Yihai
Title: Efficacy and tolerability of bevacizumab in patients with severe Covid-19 Cord-id: eu34l3dy Document date: 2021_2_5
ID: eu34l3dy
Snippet: On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesize that the anti-vascular endothelial growth factor (VEGF) drug bevacizumab might be beneficial for treating Covid-19 patients. From Feb 15 to April 5, 2020, we conducted a single-arm trial (NCT04275414) and recruited 26 patients from 2-centers (China and Italy) with severe Covid-19, with respiratory rate ≥30 times/min, oxygen saturation ≤93% with ambient air, or partial arterial oxygen pressure to frac
Document: On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesize that the anti-vascular endothelial growth factor (VEGF) drug bevacizumab might be beneficial for treating Covid-19 patients. From Feb 15 to April 5, 2020, we conducted a single-arm trial (NCT04275414) and recruited 26 patients from 2-centers (China and Italy) with severe Covid-19, with respiratory rate ≥30 times/min, oxygen saturation ≤93% with ambient air, or partial arterial oxygen pressure to fraction of inspiration O(2) ratio (PaO(2)/FiO(2)) >100 mmHg and ≤300 mmHg, and diffuse pneumonia confirmed by chest imaging. Followed up for 28 days. Among these, bevacizumab plus standard care markedly improves the PaO(2)/FiO(2) ratios at days 1 and 7. By day 28, 24 (92%) patients show improvement in oxygen-support status, 17 (65%) patients are discharged, and none show worsen oxygen-support status nor die. Significant reduction of lesion areas/ratios are shown in chest computed tomography (CT) or X-ray within 7 days. Of 14 patients with fever, body temperature normalizes within 72 h in 13 (93%) patients. Relative to comparable controls, bevacizumab shows clinical efficacy by improving oxygenation and shortening oxygen-support duration. Our findings suggest bevacizumab plus standard care is highly beneficial for patients with severe Covid-19. Randomized controlled trial is warranted.
Search related documents:
Co phrase search for related documents- active bleeding and acute ards respiratory distress syndrome: 1, 2
- acute ards respiratory distress syndrome and admission symptom onset: 1, 2, 3, 4
- acute ards respiratory distress syndrome and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and low flow oxygen: 1
- acute ards respiratory distress syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- admission time and local center: 1, 2, 3
- admission time and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- admission time and low flow oxygen: 1, 2, 3
- admission time and lung inflammation: 1, 2, 3, 4, 5, 6
- admission time and lung tissue: 1
- local center and lopinavir ritonavir: 1, 2
- local center and lung tissue: 1
- lopinavir ritonavir and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8
- lopinavir ritonavir and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date